Catalent (CTLT) Holdings Lessened by Liberty Mutual Group Asset Management Inc.

Liberty Mutual Group Asset Management Inc. trimmed its holdings in Catalent (NYSE:CTLT) by 21.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 26,167 shares of the company’s stock after selling 7,178 shares during the period. Liberty Mutual Group Asset Management Inc.’s holdings in Catalent were worth $1,074,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in CTLT. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new position in Catalent during the 4th quarter worth $242,000. Zeke Capital Advisors LLC bought a new position in Catalent during the 1st quarter worth $289,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Catalent by 45.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,325 shares of the company’s stock worth $301,000 after buying an additional 2,282 shares during the last quarter. Eagle Boston Investment Management Inc. grew its stake in Catalent by 40.0% during the 4th quarter. Eagle Boston Investment Management Inc. now owns 7,349 shares of the company’s stock worth $306,000 after buying an additional 2,101 shares during the last quarter. Finally, We Are One Seven LLC bought a new position in Catalent during the 4th quarter worth $343,000. 99.28% of the stock is currently owned by institutional investors.

Catalent opened at $39.09 on Thursday, MarketBeat Ratings reports. Catalent has a 1 year low of $33.42 and a 1 year high of $47.87. The firm has a market capitalization of $5.35 billion, a PE ratio of 24.89, a price-to-earnings-growth ratio of 2.13 and a beta of 1.53. The company has a quick ratio of 1.78, a current ratio of 2.18 and a debt-to-equity ratio of 2.53.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, May 1st. The company reported $0.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.35 by $0.06. Catalent had a return on equity of 21.76% and a net margin of 2.62%. The company had revenue of $627.90 million during the quarter, compared to analysts’ expectations of $610.47 million. During the same quarter in the prior year, the business posted $0.38 earnings per share. The company’s revenue for the quarter was up 17.9% compared to the same quarter last year. sell-side analysts predict that Catalent will post 1.55 earnings per share for the current year.

A number of brokerages recently commented on CTLT. Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research note on Thursday, May 10th. Stephens downgraded Catalent from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, February 6th. KeyCorp upgraded Catalent from a “sector weight” rating to an “overweight” rating and set a $48.00 price objective for the company in a research note on Wednesday, March 28th. UBS upgraded Catalent from a “market perform” rating to an “outperform” rating in a research note on Wednesday, March 21st. Finally, Bank of America upped their price objective on Catalent from $47.00 to $49.00 and gave the stock a “buy” rating in a research note on Tuesday, February 6th. Five equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Catalent presently has a consensus rating of “Buy” and a consensus target price of $45.67.

In other news, SVP William Downie sold 9,082 shares of the stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $41.80, for a total value of $379,627.60. Following the completion of the transaction, the senior vice president now owns 46,986 shares of the company’s stock, valued at $1,964,014.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 1.70% of the company’s stock.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply